{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:33:14Z","timestamp":1792855994326,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF, DM, or CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE, and ClinicalTrials.gov were searched from inception up to 27 August 2020. Randomized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo were included. The outcomes of interest include atrial fibrillation (AF), embolic stroke, atrial flutter (AFL), AF\/AFL, ventricular tachycardia (VT), and cardiac arrest. Relative risks (RRs) and 95% confidence intervals (CI) were pooled using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 4,532 citations, 22 trials with altogether 52,115 patients were included (mean age 63.2 years; 33,747 [64.8%] of participants were men). SGLT2i were associated with a lower risk of AF (RR 0.82, 95% CI 0.70\u20130.96), embolic stroke (RR 0.32, 95% CI 0.12\u20130.85), AF\/AFL (RR 0.82, 95% CI 0.71\u20130.95), and VT (RR 0.73, 95% CI 0.53\u20130.99), while the risk reductions in AFL (RR 0.83, 95% CI 0.58\u20131.17) and cardiac arrest (RR 0.83, 95% CI 0.61\u20131.14) did not reach statistical significance. The associations appeared to be consistent across different baseline conditions (DM vs CKD vs HF; atherosclerotic cardiovascular disease [ASCVD] vs no ASCVD) and the SGLT2i used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-021-01293-8","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T16:02:56Z","timestamp":1620403376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Hang-Long","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Kei","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-wen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Fat","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard-M. Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2145-3108","authenticated-orcid":false,"given":"Kai-Hang","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"9816","key":"1293_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6","volume":"379","author":"GY Lip","year":"2012","unstructured":"Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648\u201361.","journal-title":"Lancet"},{"issue":"8","key":"1293_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"74","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1293_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.108.821306","volume":"119","author":"E Anter","year":"2009","unstructured":"Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516\u201325.","journal-title":"Circulation"},{"issue":"17","key":"1293_CR4","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","volume":"74","author":"S Kumar","year":"2019","unstructured":"Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(17):2204\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1293_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","volume":"19","author":"S Seyed Ahmadi","year":"2020","unstructured":"Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9.","journal-title":"Cardiovasc Diabetol"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3389\/fphys.2018.01669","volume":"9","author":"LA Grisanti","year":"2018","unstructured":"Grisanti LA. Diabetes and arrhythmias: pathophysiology. Mech Ther Outcomes Front Physiol. 2018;9:1669.","journal-title":"Mech Ther Outcomes Front Physiol"},{"issue":"23","key":"1293_CR7","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","volume":"107","author":"TJ Wang","year":"2003","unstructured":"Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920\u20135.","journal-title":"Circulation"},{"issue":"1","key":"1293_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/01.CIR.84.1.40","volume":"84","author":"HR Middlekauff","year":"1991","unstructured":"Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84(1):40\u20138.","journal-title":"Circulation"},{"issue":"1","key":"1293_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/europace\/euv191","volume":"18","author":"GY Lip","year":"2016","unstructured":"Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, et al. European Heart Rhythm Association\/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2016;18(1):12\u201336.","journal-title":"Europace"},{"issue":"7","key":"1293_CR10","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/S0735-1097(00)00982-7","volume":"36","author":"J Granada","year":"2000","unstructured":"Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1293_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1067\/mhj.2002.121264","volume":"143","author":"S Baldasseroni","year":"2002","unstructured":"Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002;143(3):398\u2013405.","journal-title":"Am Heart J"},{"issue":"1","key":"1293_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12933-018-0779-8","volume":"17","author":"HV Tran","year":"2018","unstructured":"Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CI, Goldberg RJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2018;17(1):136.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"1293_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1293_CR14","doi-asserted-by":"publisher","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"1293_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","volume":"18","author":"Y Fei","year":"2019","unstructured":"Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):112.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1293_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262-75.e9.","journal-title":"J Am Soc Hypertens"},{"issue":"15","key":"1293_CR17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"5","key":"1293_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495\u2013502.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1293_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/ejhf.1663","volume":"22","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020;22(1):126\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1293_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","volume":"19","author":"HY Chen","year":"2020","unstructured":"Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1293_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","volume":"20","author":"BM Bonora","year":"2021","unstructured":"Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol. 2021;20(1):39.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1293_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/dom.13077","volume":"20","author":"F Persson","year":"2018","unstructured":"Persson F, Nystr\u00f6m T, J\u00f8rgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20(2):344\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"1293_CR23","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2011."},{"key":"1293_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1293_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa065","author":"HL Li","year":"2020","unstructured":"Li HL, Feng Q, Tsoi MF, Fei Y, Cheung BMY. Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa065.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1293_CR26","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7650","key":"1293_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"1293_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.","journal-title":"BMC Med"},{"issue":"4","key":"1293_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531\u201341.","journal-title":"Diabet Med"},{"issue":"3","key":"1293_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, Stenl\u00f6f K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294\u2013303.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1293_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P, Gonz\u00e1lez-G\u00e1lvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267\u201382.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"1293_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"1293_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218\u201327.","journal-title":"Diabetes Care"},{"issue":"4","key":"1293_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"1293_CR35","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"22","key":"1293_CR36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"1293_CR37","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.12149","volume":"15","author":"N Inagaki","year":"2013","unstructured":"Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15(12):1136\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1293_CR38","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252\u201362.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1293_CR39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1293_CR40","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773-88.e1.","journal-title":"Clin Ther"},{"issue":"11","key":"1293_CR41","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009\u201317.","journal-title":"Diabetes Care"},{"issue":"2","key":"1293_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"S\u00f8fteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind. Parallel-Group Trial Diabetes Care. 2017;40(2):201\u20139.","journal-title":"Parallel-Group Trial Diabetes Care"},{"issue":"6","key":"1293_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405\u201315.","journal-title":"Ann Intern Med"},{"issue":"10","key":"1293_CR44","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1293_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1293_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL Randomized Study. Diabetes Ther. 2018;9(1):49\u201366.","journal-title":"Diabetes Ther"},{"issue":"24","key":"1293_CR47","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"1293_CR48","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713\u201322.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"1293_CR49","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"10166","key":"1293_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"1","key":"1293_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","volume":"18","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chang KC, Hung MJ, Yang NI, Chan YY, Chen HY, et al. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovasc Diabetol. 2019;18(1):120.","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"1293_CR52","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/dom.13295","volume":"20","author":"M Guo","year":"2018","unstructured":"Guo M, Ding J, Li J, Wang J, Zhang T, Liu C, et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(8):1977\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1293_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/20009666.2018.1514932","volume":"8","author":"SR Shah","year":"2018","unstructured":"Shah SR, Luu SW, Calestino M, David J, Christopher B. Management of atrial fibrillation-flutter: uptodate guideline paper on the current evidence. J Community Hosp Intern Med Perspect. 2018;8(5):269\u201375.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"1","key":"1293_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","volume":"19","author":"WJ Li","year":"2020","unstructured":"Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19(1):130.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"1293_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1293_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19(1):148.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1293_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-020-01043-2","volume":"19","author":"YH Chan","year":"2020","unstructured":"Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, et al. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol. 2020;19(1):63.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1293_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12933-020-01180-8","volume":"19","author":"C Sardu","year":"2020","unstructured":"Sardu C, Paolisso P, Ducceschi V, Santamaria M, Sacra C, Massetti M, et al. Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators. Cardiovasc Diabetol. 2020;19(1):202.","journal-title":"Cardiovasc Diabetol."},{"issue":"9","key":"1293_CR59","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401\u201338.","journal-title":"Arch Toxicol"},{"issue":"6","key":"1293_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.14740\/jocmr3011w","volume":"9","author":"M Sano","year":"2017","unstructured":"Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res. 2017;9(6):457\u201360.","journal-title":"J Clin Med Res"},{"issue":"5","key":"1293_CR61","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471\u20136.","journal-title":"J Cardiol"},{"issue":"23","key":"1293_CR62","doi-asserted-by":"publisher","first-page":"e018889","DOI":"10.1161\/JAHA.120.018889","volume":"9","author":"E Gronda","year":"2020","unstructured":"Gronda E, Jessup M, Iacoviello M, Palazzuoli A, Napoli C. Glucose metabolism in the kidney: neurohormonal activation and heart failure development. J Am Heart Assoc. 2020;9(23):e018889.","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"1293_CR63","doi-asserted-by":"publisher","first-page":"e0235640","DOI":"10.1371\/journal.pone.0235640","volume":"15","author":"BG Han","year":"2020","unstructured":"Han BG, Lee JY, Kim MR, Shin H, Kim JS, Yang JW, et al. Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis. PLoS ONE. 2020;15(7):e0235640.","journal-title":"PLoS ONE"},{"issue":"6","key":"1293_CR64","doi-asserted-by":"publisher","first-page":"147916412097122","DOI":"10.1177\/1479164120971220","volume":"17","author":"T Hiramatsu","year":"2020","unstructured":"Hiramatsu T, Ito H, Okumura S, Asano Y, Iguchi D, Furuta S. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment. Diab Vasc Dis Res. 2020;17(6):1479164120971220.","journal-title":"Diab Vasc Dis Res"},{"issue":"9","key":"1293_CR65","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025\u20139.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1293_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"E Bertero","year":"2018","unstructured":"Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12\u20138.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1293_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","volume":"19","author":"SR Yurista","year":"2020","unstructured":"Yurista SR, Sillj\u00e9 HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020;19(1):5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1293_CR68","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):165.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1293_CR69","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190\u20135.","journal-title":"Diabetes"},{"issue":"7","key":"1293_CR70","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"issue":"3","key":"1293_CR71","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCEP.108.817320","volume":"2","author":"AS Barth","year":"2009","unstructured":"Barth AS, Tomaselli GF. Cardiac metabolism and arrhythmias. Circ Arrhythm Electrophysiol. 2009;2(3):327\u201335.","journal-title":"Circ Arrhythm Electrophysiol"}],"updated-by":[{"DOI":"10.1186\/s12933-021-01371-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01293-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T10:02:43Z","timestamp":1630749763000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01293-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-021-01371-x","URL":"https:\/\/doi.org\/10.1186\/s12933-021-01371-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}